Features

CooperVision GSLS 2024 Scientific Program Advances Myopia Control & Irregular Cornea Care

MiSight® 1 day Efficacy for Fast/Slow Progressors, Pediatric Prescribing Trends, and Scleral Lens Use for Dry Eye Among Research Papers and Posters Highlights

Latest CORE Publication Offers Specialty Contact Lens and Myopia Management Insights for Practitioners

Advancements in and increased fitting of scleral and corneo-scleral lenses, plus resurgent interest surrounding orthokeratology for managing myopia control, sets the stage for Issue 76 of Contact Lens Update.

Oral Drug Slows Stargardt Disease Progression in Phase 2 Clinical Trial

Results from a Phase 2 clinical trial show that an oral drug, Tinlarebant, may slow progression of Stargardt disease.

Dynamic & Comprehensive VisionEd Conference Program Announced for VEE 2024

The Vision Council and RX, co-organizers of Vision Expo, bring compelling accredited continuing education offerings to the industry at Vision Expo East 2024.

Balancing Style and Functionality in Frame Selection

From the moment a patient steps into the dispensary, they are met with a unique prescription and a set of preferences.

1 61 62 63 64 65 478

CooperVision GSLS 2024 Scientific Program Advances Myopia Control & Irregular Cornea Care

MiSight® 1 day Efficacy for Fast/Slow Progressors, Pediatric Prescribing Trends, and Scleral Lens Use for Dry Eye Among Research Papers and Posters Highlights

Latest CORE Publication Offers Specialty Contact Lens and Myopia Management Insights for Practitioners

Advancements in and increased fitting of scleral and corneo-scleral lenses, plus resurgent interest surrounding orthokeratology for managing myopia control, sets the stage for Issue 76 of Contact Lens Update.

Oral Drug Slows Stargardt Disease Progression in Phase 2 Clinical Trial

Results from a Phase 2 clinical trial show that an oral drug, Tinlarebant, may slow progression of Stargardt disease.

Dynamic & Comprehensive VisionEd Conference Program Announced for VEE 2024

The Vision Council and RX, co-organizers of Vision Expo, bring compelling accredited continuing education offerings to the industry at Vision Expo East 2024.

Balancing Style and Functionality in Frame Selection

From the moment a patient steps into the dispensary, they are met with a unique prescription and a set of preferences.

1 61 62 63 64 65 478

CooperVision GSLS 2024 Scientific Program Advances Myopia Control & Irregular Cornea Care

MiSight® 1 day Efficacy for Fast/Slow Progressors, Pediatric Prescribing Trends, and Scleral Lens Use for Dry Eye Among Research Papers and Posters Highlights

Latest CORE Publication Offers Specialty Contact Lens and Myopia Management Insights for Practitioners

Advancements in and increased fitting of scleral and corneo-scleral lenses, plus resurgent interest surrounding orthokeratology for managing myopia control, sets the stage for Issue 76 of Contact Lens Update.

Oral Drug Slows Stargardt Disease Progression in Phase 2 Clinical Trial

Results from a Phase 2 clinical trial show that an oral drug, Tinlarebant, may slow progression of Stargardt disease.

Dynamic & Comprehensive VisionEd Conference Program Announced for VEE 2024

The Vision Council and RX, co-organizers of Vision Expo, bring compelling accredited continuing education offerings to the industry at Vision Expo East 2024.

Balancing Style and Functionality in Frame Selection

From the moment a patient steps into the dispensary, they are met with a unique prescription and a set of preferences.

1 61 62 63 64 65 478

CooperVision GSLS 2024 Scientific Program Advances Myopia Control & Irregular Cornea Care

MiSight® 1 day Efficacy for Fast/Slow Progressors, Pediatric Prescribing Trends, and Scleral Lens Use for Dry Eye Among Research Papers and Posters Highlights

Latest CORE Publication Offers Specialty Contact Lens and Myopia Management Insights for Practitioners

Advancements in and increased fitting of scleral and corneo-scleral lenses, plus resurgent interest surrounding orthokeratology for managing myopia control, sets the stage for Issue 76 of Contact Lens Update.

Oral Drug Slows Stargardt Disease Progression in Phase 2 Clinical Trial

Results from a Phase 2 clinical trial show that an oral drug, Tinlarebant, may slow progression of Stargardt disease.

Dynamic & Comprehensive VisionEd Conference Program Announced for VEE 2024

The Vision Council and RX, co-organizers of Vision Expo, bring compelling accredited continuing education offerings to the industry at Vision Expo East 2024.

Balancing Style and Functionality in Frame Selection

From the moment a patient steps into the dispensary, they are met with a unique prescription and a set of preferences.

1 61 62 63 64 65 478